PURPOSE OF REVIEW: The aim of this study was to summarize the available evidence on different PET imaging modalities for the staging of patients diagnosed with bladder cancer (BCa). We further discuss the use of PET/computed tomography (CT) and PET/MRI with different radiopharmaceuticals to characterize tumour biology for treatment guidance. RECENT FINDINGS: Available evidence supports the benefits of PET/CT in BCa staging due to its higher accuracy in the detection of nodal metastases compared with CT alone. The use of PET/MRI is of major future interest due to the higher soft tissue contrast of MRI, which might enable the early detection of the tumour in the bladder. For the time being, the sensitivity of PET/MRI is still too low, when it comes to the diagnosis of early-stage BCa. This is mainly due to the renal excretion of the commonly used [ 18 F]FDG PET tracer, wherefore small lesions in the wall of the bladder can be missed. Novel studies using PET radiopharmaceuticals to target immune checkpoints or other immune cell targets (immunoPET) demonstrated high uptake in tumour lesions with high PD-L1 expression. The use of immunoPET could therefore help identify BCa patients who exhibit PD-L1 positive tumours for systemic immune-therapy. SUMMARY: PET/CT and PET/MRI seem to be promising imaging tools in BCa staging, especially for the detection of lymph node and distant metastases, as they are more accurate than conventional CT. Future clinical trials with novel radiopharmaceuticals and machine-learning driven PET-technologies bear the potential to help in the early detection, staging, monitoring and precision-medicine approach. Specifically, immunoPET is of high future interest, as it could help develop the concept of precision-medicine in the age of immunotherapy.

Department of Biomedical Imaging and Image guided Therapy Division of Nuclear Medicine

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology University of Texas Southwestern Dallas Texas USA

Department of Urology Weill Cornell Medical College New York New York

Division of Urology Department of Special Surgery Jordan University Hospital The University of Jordan Amman Jordan

Institute for Urology and Reproductive Health Sechenov University Moscow Russia

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Zobrazit více v PubMed

Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 2018; 73:111–122.

Omorphos NP, Ghose A, Hayes JDB, et al. The increasing indications of FDG-PET/CT in the staging and management of invasive bladder cancer. Urol Oncol 2022; 40:434–441.

Abouelkheir RT, Abdelhamid A, Abou El-Ghar M, El-Diasty T. Imaging of bladder cancer: standard applications and future trends. Medicina 2021; 57:220.

Aydh A, Abufaraj M, Mori K, et al. Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review. Arab J Urol 2020; 19:59–66.

Bouchelouche K. PET/CT in bladder cancer: an update. Semin Nucl Med 2022; 52:475–485.

Ha HK, Koo PJ, Kim S-J. Diagnostic accuracy of F-18 FDG PET/CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis. Oncology 2018; 95:31–38.

Girard A, Vila Reyes H, Shaish H, et al. The role of 18F-FDG PET/CT in guiding precision medicine for invasive bladder carcinoma. Front Oncol 2020; 10:565086.

Kibel AS, Dehdashti F, Katz MD, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009; 27:4314–4320.

Drieskens O, Oyen R, Van Poppel H, et al. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 2005; 32:1412–1417.

Aljabery F, Lindblom G, Skoog S, et al. PET/CT versus conventional CT for detection of lymph node metastases in patients with locally advanced bladder cancer. BMC Urol 2015; 15:87.

Swinnen G, Maes A, Pottel H, et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 2010; 57:641–647.

Mertens LS, Meijer RP, Alfred Witjes J. Positron emission tomography/computed tomography for staging of bladder cancer: a continuing clinical controversy. Eur Urol 2023; 83:95–96.

Mertens LS, Bruin NM, Vegt E, et al. Catheter-assisted 18F-FDG-PET/CT imaging of primary bladder cancer: a prospective study. Nucl Med Commun 2012; 33:1195–1201.

Mansi L, Ciarmiello A, Cuccurullo V. PET/MRI and the revolution of the third eye. Eur J Nucl Med Mol Imaging 2012; 39:1519–1524.

Catalano OA, Rosen BR, Sahani DV, et al. Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients: a hypothesis-generating exploratory study. Radiology 2013; 269:857–869.

Civelek AC, Niglio SA, Malayeri AA, et al. Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. Urol Oncol 2021; 39:787.e17–787.e21.

Eulitt PJ, Altun E, Sheikh A, et al. Pilot study of [18F] fluorodeoxyglucose positron emission tomography (FDG-PET)/magnetic resonance imaging (MRI) for staging of muscle-invasive bladder cancer (MIBC). Clin Genitourin Cancer 2020; 18:378–386.e1.

Rosenkrantz AB, Friedman KP, Ponzo F, et al. Prospective pilot study to evaluate the incremental value of PET information in patients with bladder cancer undergoing 18F-FDG simultaneous PET/MRI. Clin Nucl Med 2017; 42:e8–e15.

Cuccurullo V, Di Stasio GD, Manti F, et al. The role of molecular imaging in a muscle-invasive bladder cancer patient: a narrative review in the era of multimodality treatment. Diagnostics (Basel) 2021; 11.

Partovi S, Kohan A, Rubbert C, et al. Clinical oncologic applications of PET/MRI: a new horizon. Am J Nucl Med Mol Imaging 2014; 4:202–212.

Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 2019; 60:801–805.

Novruzov E, Dendl K, Ndlovu H, et al. Head-to-head intra-individual comparison of [68Ga]-FAPI and [18F]-FDG PET/CT in patients with bladder cancer. Mol Imaging Biol 2022; 24:651–658.

Unterrainer LM, Lindner S, Eismann L, et al. Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma. Eur J Nucl Med Mol Imaging 2022; 49:3571–3580.

Wei W, Rosenkrans ZT, Liu J, et al. ImmunoPET: concept, design, and applications. Chem Rev 2020; 120:3787–3851.

Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 2016; 9:5023–5039.

Yi M, Niu M, Xu L, et al. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol 2021; 14:10.

Zhang Y, Hong H, Cai W. PET tracers based on Zirconium-89. Curr Radiopharm 2011; 4:131–139.

De Feo MS, Pontico M, Frantellizzi V, et al. 89Zr-PET imaging in humans: a systematic review. Clin Transl Imaging 2022; 10:23–36.

van de Watering FCJ, Rijpkema M, Perk L, et al. Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients. Biomed Res Int 2014; 2014:203601.

Bensch F, van der Veen EL, Lub-de Hooge MN, et al. 89Zr-atezolizumab imaging as a noninvasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med 2018; 24:1852–1858.

Chen R, Zhou X, Liu J, Huang G. Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer. Eur J Nucl Med Mol Imaging 2019; 46:848–854.

Differential performance of imaging modalities predicting pathological response to neoadjuvant chemotherapy in urothelial bladder cancer: a systematic review and meta-analysis

Upper Tract Urothelial Carcinoma: A Narrative Review of Current Surveillance Strategies for Non-Metastatic Disease